Durata Therapeutics, Inc. Reports First Quarter 2014 Financial Results

CHICAGO, May 8, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the quarter ended March 31, 2014.

"The first quarter of 2014 ended on a high note with the unanimous recommendation by the FDA's Anti-Infective Drugs Advisory Committee for the approval of Dalvance," said Paul R. Edick, CEO of Durata Therapeutics. "We are very focused on several major milestones, which include preparing for the May 26th action date for the FDA's review of our NDA and an anticipated launch of Dalvance in the third quarter of 2014, as well as advancing additional studies of dalbavancin, among other initiatives."

Help employers find you! Check out all the jobs and post your resume.